We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+31.65%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$588M
AUM Growth
+$90.2M
Cap. Flow
-$14.6M
Cap. Flow %
-2.49%
Top 10 Hldgs %
70.6%
Holding
33
New
4
Increased
8
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$40.5M
2
BLRX
BioLineRX
BLRX
+$18.8M
3
CTMX icon
CytomX Therapeutics
CTMX
+$16.4M
4
LOXO
Loxo Oncology, Inc
LOXO
+$13.2M
5
XOMA
Xoma
XOMA
+$6.17M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$41.3M
2
ARRY
Array Biopharma Inc
ARRY
+$23.7M
3
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$17.6M
4
ESPR
Esperion Therapeutics
ESPR
+$8.92M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$8.5M

Sector Composition

Rank Sector Weight
1 Healthcare 75.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$84.1M 14.3%
2,102,280
-1,153,000
-35% -$41.3M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$58.2M 9.89%
7,990,572
+192,000
+2% +$1.38M
CYTK icon
3
Cytokinetics
CYTK
$10.9B
$54.8M 9.31%
4,260,836
-590,855
-12% -$6.91M
ANAB icon
4
AnaptysBio
ANAB
$1.63B
$48.2M 8.21%
+1,738,600
New +$40.5M
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$39.9M 6.78%
2,336,609
-279,640
-11% -$3.35M
CTMX icon
6
CytomX Therapeutics
CTMX
$714M
$31.2M 5.3%
1,804,675
+1,249,869
+225% +$16.4M
FWP
7
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$29.9M 5.09%
198,265
– –
INFI
8
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$25.4M 4.32%
7,866,108
+5,300
+0.1% +$13K
ARRY
9
DELISTED
Array Biopharma Inc
ARRY
$24.7M 4.2%
2,763,086
-2,223,100
-45% -$23.7M
CTIC
10
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$18.8M 3.2%
4,479,691
-3
-0% -$14
BLRX
11
BioLineRX
BLRX
$11.7M
$16.8M 2.86%
+29,167
New +$18.8M
OMED
12
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$16.2M 2.76%
1,760,489
– –
CBIO
13
Crescent Biopharma
CBIO
$555M
$15.3M 2.61%
28,263
– –
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
$13.8M 2.35%
3,285,400
+862,100
+36% +$3.58M
LOXO
15
DELISTED
Loxo Oncology, Inc
LOXO
$13.5M 2.29%
+320,000
New +$13.2M
CASC
16
DELISTED
Cascadian Therapeutics, Inc.
CASC
$13M 2.21%
3,133,224
– –
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.2B
$11.8M 2.01%
2,949,794
-94,011
-3% -$739K
XOMA
18
DELISTED
Xoma
XOMA
$10.7M 1.82%
1,502,800
+1,200,000
+396% +$6.17M
FATE icon
19
Fate Therapeutics
FATE
$293M
$8.85M 1.51%
1,945,245
-1,814,153
-48% -$6.64M
IMDZ
20
DELISTED
Immune Design Corp.
IMDZ
$8.39M 1.43%
1,233,976
-86,188
-7% -$498K
ARQL
21
DELISTED
Arqule Inc
ARQL
$7.84M 1.33%
7,400,128
– –
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$6.32M 1.07%
44,009
+4,217
+11% +$603K
ALPN
23
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.44M 0.93%
466,119
– –
ONCT
24
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.39M 0.92%
7,917
– –
PVLA
25
Palvella Therapeutics
PVLA
$2.15B
$4.98M 0.85%
23,963
+778
+3% +$138K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2017 Portfolio in Review

As of Q1 2017, BVF Inc held 33 positions worth $588M, up 18% from $498M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

BVF Inc's Q1 2017 filing shows 4 new, 8 increased, 8 reduced and 3 closed positions. Its largest new stake was AnaptysBio: 1,738,600 shares worth $48.2M. The largest sale was Blueprint Medicines, an estimated $41.3M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier.

  • BVF Inc's largest Q1 2017 buy was AnaptysBio: 1,738,600 shares worth $48.2M.
  • BVF Inc added most to CytomX Therapeutics in Q1 2017, an estimated $16.4M increase.
  • BVF Inc's biggest Q1 2017 reduction was Blueprint Medicines, cutting an estimated $41.3M.
  • BVF Inc fully exited CoLucid Pharmaceuticals, Inc. in Q1 2017, selling an estimated $17.6M.
  • BVF Inc's ten largest holdings make up 71% of its $588M portfolio in Q1 2017.
  • BVF Inc opened 4 new positions and closed 3 in Q1 2017.
  • BVF Inc's portfolio value rose 18% quarter-over-quarter to $588M.

Based on BVF Inc's 13F filing for Q1 2017, filed 15 May 2017.